La Jolla, CANCT06482268Now EnrollingIRB Ready

PD - Parkinson's Disease Clinical Trial in La Jolla, CA

Access cutting-edge pd - parkinson's disease treatment through this phase 1 clinical trial at a research site in La Jolla. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Diego

Quick Self-Assessment

See if you qualify for this La Jolla location

Preparing your pre-screening questions…

Expert Care in La Jolla

Access pd - parkinson's disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pd - parkinson's disease treatment provided free

Apply for This La Jolla Location

Check if you qualify for this pd - parkinson's disease clinical trial in La Jolla, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to La Jolla

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit La Jolla site if eligible
  4. 4Begin participation

About This PD - Parkinson's Disease Study in La Jolla

To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease

Sponsor: University of California, San Diego

Who Can Participate

Inclusion Criteria

The subject has a diagnosis of PD (clinically established or clinically probable) in accordance with the MDS Clinical Diagnostic Criteria for Parkinson's Disease (2015).
The subject has an inadequate response to drug treatments.
The subject is ≥ 40 years and ≤ 75 years of age at the time of informed consent.
The subject has had PD for at least 5 years.
The subject has both ON and OFF (as demonstrated by the MDS-UPDRS Part III and a symptom diary).
The subject does not have a debilitating dyskinesia score greater than or equal to 3 on the MDS-UPDRS.
The subject is in stage 2 or higher on the Hoehn and Yahr scale at OFF time.
The subject is in stage 3 or lower on the Hoehn and Yahr scale at ON time.
The subject has an L-dopa response of 30% or more without influence of antiparkinsonian drugs.
The subject has the following organ functions as determined by laboratory tests at Screening visit:
Neutrophil count ≥ 2,000/μL
Platelet count ≥ 5.0 × 104/μL
AST, ALT ≤ 3.0 × upper limit of normal
Total bilirubin ≤ 1.5 × upper limit of normal
eGFR ≥ 60 mL/min/1.73 m2 (As part of Creatinine testing, an estimated glomerular filtration rate (mL/min/1.73 m2)will be calculated based on the CKD-EPI 2021 equation)
The subject is willing to avoid pregnancy using abstinence, highly effective means of birth control, surgical sterility, or menopause.
The subject is willing to comply with the protocol-required assessments.
The subject provides written informed consent to participate in the study. If the subject cannot sign due to physical constraints, verbal consent may be provided with signature of a Legally Authorized Representative.

Exclusion Criteria

The subject has an abnormal brain MRI suggestive of brain pathology other than Parkinson's disease.
Atypical parkinsonism (Parkinsonism-Plus syndrome, secondary parkinsonism, hereditary parkinsonism).
The subject has clinical indication or diagnosis of abnormal immune function.
The subject has been diagnosed with a major neurocognitive disorder such as dementia, or is high risk for this.
The subject has bleeding tendency or abnormal coagulation function as evidenced by platelets \<50 or PT/PTT \> 1.5x normal.
The subject is HBs antigen-positive, or HBs antibody- or HBc antibody-positive with evidence of HBV-DNA.
The subject is anti-HIV antibody positive.
The subject is anti-HTLV-1 antibody-positive.
The subject has active infection such as hepatitis C or syphilis (STS/TPHA).
The subject has hypersensitivity or contraindication to tacrolimus, concomitant drugs (e.g., levodopa, carbidopa, MRI contrast), and/or their components.
Contraindications to general anesthesia as evaluated by subject matter experts.
The subject has a serious allergy to a component (e.g., gentamicin, component of bovine origin, or component of porcine origin) used in the preparation of the study product.
The subject has any of the following conditions/diseases concurrently:
Malignant neoplasm
Psychiatric disease (e.g., uncontrolled anxiety or depression, bipolar disorder, schizophrenia)
Diabetes mellitus with poorly controlled blood glucose (glycosylated hemoglobin \> 9.0%, or fasting plasma glucose (FPG) ≥ 200 mg/dL (11.1 mmol/L).
Other serious concurrent diseases (e.g., cerebrovascular disorder, heart disease, chronic respiratory disease, inadequately controlled hypertension) as determined by the investigator.
The subject has a history of any of the following:
Prior malignancy \< 5 years prior to Screening. Patients who had prior malignancies within 5 years and in complete remission with expected survival of more than 5 years are not excluded
Cerebral hemorrhage or stroke
Psychiatric disease (e.g., uncontrolled anxiety or depression, bipolar disorder, schizophrenia)
Congenital long QT syndrome
Pallidotomy, thalamotomy, or Deep Brain Stimulation
The subject is pregnant or lactating or does not agree to avoid pregnancy throughout the study.
The subject has undergone transplantation of human iPSC-derived dopaminergic progenitors.
The subject, in the opinion of the investigator or sub investigator, is not appropriate to conduct the study safely.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in La Jolla?

Yes, this clinical trial (NCT06482268) has an active research site in La Jolla, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

PD - Parkinson's Disease Treatment Options in La Jolla, CA

If you're searching for pd - parkinson's disease treatment options in La Jolla, CA, this clinical trial (NCT06482268) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our La Jolla research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced pd - parkinson's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pd - parkinson's disease clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in La Jolla, CA

See all parkinsons disease clinical trials recruiting in La Jolla — not just this study.

Browse Parkinsons Disease Trials in La Jolla →

Browse More Trials by Condition

Parkinsons Disease TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in La Jolla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · La Jolla, CA